Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025

Reuters

Jun 13, 2025

Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025

Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug $(IND.AU)$ filing expected by the end of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2543297686"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543297686\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543297686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543297686","market":"us","top_or_hot":-1,"title":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL4kcym4:1","article_id":"2543297686","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543297686","pubTimestamp":1749812433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025. Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug  filing expected by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1588":"回港中概股","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"再鼎医药在2025年EAACI大会上公布了ZL-1503作为中重度特应性皮炎新疗法的有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":0.9},"content_text":"Zai Lab Unveils Promising Preclinical Results for ZL-1503 as Novel Treatment for Moderate-to-Severe Atopic Dermatitis at EAACI Congress 2025\n    \n\n        Zai Lab Ltd. has announced promising preclinical data for their bispecific antibody, ZL-1503, aimed at treating moderate-to-severe atopic dermatitis and other conditions driven by IL-13 and IL-31. The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, highlight ZL-1503's ability to simultaneously suppress inflammatory and pruritogenic pathways, offering a potential novel treatment option. The preclinical study demonstrated a favorable safety profile, prolonged half-life, and durable suppression of disease pathways in non-human primates. Zai Lab plans to advance ZL-1503 to IND-enabling studies with an Investigational New Drug $(IND.AU)$ filing expected by the end of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613588431) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}